BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 16, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 16 new employees in restricted stock units for an aggregate of 71,146 shares of the Company's common stock, with the effective date of March 18, 2024. One-fourth of the shares underlying each employee's restricted stock units will vest on February 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the "Plan").
加利福尼亚州帕洛阿尔托，2024 年 3 月 20 日（GLOBE NEWSWIRE）——专注于遗传性疾病和癌症的商业阶段生物制药公司 BridgeBio Pharma, Inc.（纳斯达克股票代码：BBIO）（“BridgeBio” 或 “公司”）今天宣布，BridgeBio 董事会薪酬委员会于 2024 年 3 月 16 日批准向 16 名新员工提供限制性股票单位的股权补助公司普通股共计71,146股，生效日期为2024年3月18日。每位员工的限制性股票单位所依据的四分之一的股份将在2025年2月16日归属，此后每位员工的限制性股票单位的剩余股份的十二分之一将按季度归属，前提是每位此类员工在该归属日期继续在公司或其子公司工作。上述所有奖励均根据BridgeBio的经修订和重述的2019年激励股权计划（“计划”）发放。
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.
根据纳斯达克上市规则5635（c）（4），上述每项奖励都是作为激励材料发放的，是根据该计划的条款发放的。该计划于2019年11月由BridgeBio董事会通过，并于2023年2月10日和2023年12月13日进行了修订和重申。
About BridgeBio Pharma, Inc.
关于 BridgeBio 制药公司
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Contact:
布里奇生物联系人：
Vikram Bali
contact@bridgebio.com
(650)-789-8220
巴厘岛维克拉姆
contact@bridgebio.com
(650) -789-8220